Crossmark

A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database

Crossref DOI link: https://doi.org/10.1038/s41598-024-55829-5

Published Online: 2024-04-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sun, Rui

Ning, Zhen

Qin, Henan

Zhang, Wenhe

Teng, Yibin

Jin, Chenxing

Liu, Jiwei

Wang, Aman
Funding

Funding for this research was provided by:

the National Natural Science Foundation of China grants (No. 81802272)
License Information

Text and Data Mining valid from 2024-04-25

Version of Record valid from 2024-04-25
More Information

Article History

Received: 8 January 2024

Accepted: 28 February 2024

First Online: 25 April 2024

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below